Study Statistics

StudyRR [95% Conf. Interval]% Weight
Rosenstock, 20080.7110.3001.6813.67
Rosenstock, 20090.6750.4580.99518.10
Defronzo, 20090.6120.4440.84426.39
Hollander, 20090.7380.5021.08718.20
Chacra, 20090.6630.4980.88133.64
D+L pooled RR0.6660.5650.785100.00

Heterogeneity chi-squared = 0.57 (d.f. = 4) P=0.967

I-squared (variation in RR attributable to heterogeneity) = 0.0%

Estimate of between-study variance Tau-squared = 0.0000

Test of RR=1 : z= 4.83 P=0.000

From: Appendix E, Meta-analyses

Cover of Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations
Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations: Final Original Report [Internet].
Jonas D, Van Scoyoc E, Gerrald K, et al.
Portland (OR): Oregon Health & Science University; 2011 Feb.
Copyright © 2011, Oregon Health & Science University.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.